307 related articles for article (PubMed ID: 37800107)
1. The Cardiovascular Effect of Tirzepatide: A Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide Dual Agonist.
Cho YK; La Lee Y; Jung CH
J Lipid Atheroscler; 2023 Sep; 12(3):213-222. PubMed ID: 37800107
[TBL] [Abstract][Full Text] [Related]
2. The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials.
Min T; Bain SC
Diabetes Ther; 2021 Jan; 12(1):143-157. PubMed ID: 33325008
[TBL] [Abstract][Full Text] [Related]
3. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists.
Urva S; Coskun T; Loghin C; Cui X; Beebe E; O'Farrell L; Briere DA; Benson C; Nauck MA; Haupt A
Diabetes Obes Metab; 2020 Oct; 22(10):1886-1891. PubMed ID: 32519795
[TBL] [Abstract][Full Text] [Related]
4. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
Fisman EZ; Tenenbaum A
Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
[TBL] [Abstract][Full Text] [Related]
5. Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice.
Bradley CL; McMillin SM; Hwang AY; Sherrill CH
Ann Pharmacother; 2023 Jul; 57(7):822-836. PubMed ID: 36367094
[TBL] [Abstract][Full Text] [Related]
6. Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes.
Frías JP
Expert Rev Endocrinol Metab; 2020 Nov; 15(6):379-394. PubMed ID: 33030356
[TBL] [Abstract][Full Text] [Related]
7. Beyond glycemia: Comparing tirzepatide to GLP-1 analogues.
Andraos J; Muhar H; Smith SR
Rev Endocr Metab Disord; 2023 Dec; 24(6):1089-1101. PubMed ID: 37526853
[TBL] [Abstract][Full Text] [Related]
8. Tirzepatide: Does the Evidence to Date Show Potential for the Treatment of Early Stage Type 2 Diabetes?
Razzaki TS; Weiner A; Shukla AP
Ther Clin Risk Manag; 2022; 18():955-964. PubMed ID: 36199834
[TBL] [Abstract][Full Text] [Related]
9. The importance of glucose-dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide.
Gasbjerg LS; Rosenkilde MM; Meier JJ; Holst JJ; Knop FK
Diabetes Obes Metab; 2023 Nov; 25(11):3079-3092. PubMed ID: 37551549
[TBL] [Abstract][Full Text] [Related]
10. Tirzepatide: A Review in Type 2 Diabetes.
France NL; Syed YY
Drugs; 2024 Feb; 84(2):227-238. PubMed ID: 38388874
[TBL] [Abstract][Full Text] [Related]
11. Role of a Dual Glucose-Dependent Insulinotropic Peptide (GIP)/Glucagon-like Peptide-1 Receptor Agonist (Twincretin) in Glycemic Control: From Pathophysiology to Treatment.
Pelle MC; Provenzano M; Zaffina I; Pujia R; Giofrè F; Lucà S; Andreucci M; Sciacqua A; Arturi F
Life (Basel); 2021 Dec; 12(1):. PubMed ID: 35054422
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes.
De Block CEM; Dirinck E; Verhaegen A; Van Gaal LF
Diabetes Obes Metab; 2022 May; 24(5):788-805. PubMed ID: 34984793
[TBL] [Abstract][Full Text] [Related]
13. Tirzepatide: A Dual Glucose-dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Agonist for the Management of Type 2 Diabetes Mellitus.
Wong E; Cope R; Dima L; Nguyen T
Am J Ther; 2023 Jan-Feb 01; 30(1):e26-e35. PubMed ID: 36516422
[TBL] [Abstract][Full Text] [Related]
14. Tirzepatide - a dual GIP/GLP-1 receptor agonist - a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes.
Nowak M; Nowak W; Grzeszczak W
Endokrynol Pol; 2022; 73(4):745-755. PubMed ID: 35593668
[TBL] [Abstract][Full Text] [Related]
15. A Case Report of Systemic Allergic Reaction to the Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonist Tirzepatide.
Le TTB; Minh LHN; Devi P; Islam N; Sachmechi I
Cureus; 2024 Jan; 16(1):e51460. PubMed ID: 38298324
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease-Current Evidence.
Muzurović EM; Volčanšek Š; Tomšić KZ; Janež A; Mikhailidis DP; Rizzo M; Mantzoros CS
J Cardiovasc Pharmacol Ther; 2022; 27():10742484221146371. PubMed ID: 36546652
[TBL] [Abstract][Full Text] [Related]
17. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.
Karagiannis T; Avgerinos I; Liakos A; Del Prato S; Matthews DR; Tsapas A; Bekiari E
Diabetologia; 2022 Aug; 65(8):1251-1261. PubMed ID: 35579691
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin: An update including recently developed glucagon-like peptide-1 (GLP-1) receptor agonists and the glucose-dependent insulinotropic polypeptide/GLP-1 receptor co-agonist tirzepatide.
Nauck MA; Mirna AEA; Quast DR
Diabetes Obes Metab; 2023 May; 25(5):1361-1371. PubMed ID: 36700380
[TBL] [Abstract][Full Text] [Related]
19. Tirzepatide: A novel cardiovascular protective agent in type 2 diabetes mellitus and obesity.
Sardar MB; Nadeem ZA; Babar M
Curr Probl Cardiol; 2024 May; 49(5):102489. PubMed ID: 38417475
[TBL] [Abstract][Full Text] [Related]
20. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.
Nauck MA; D'Alessio DA
Cardiovasc Diabetol; 2022 Sep; 21(1):169. PubMed ID: 36050763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
